Evidence map›Paper›PMID 41675056›Full record

ReviewiScience2026

Integrating CAR-T therapy with PD-1/PD-L1 blockade: Mechanisms, synergy, and optimized strategies in NSCLC.

Xingxing Li, Zitong Wang, Shuyang Mao, Yijun Zhao, Jiayi Ye, Beibei Liang, Jialei Peng, Xinyi Xie, Jinglan Pan, Chunhai Xiao and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xingxing LiGraduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zitong WangDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Shuyang MaoDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Yijun ZhaoGraduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jiayi YeGraduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Beibei LiangDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Jialei PengDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Xinyi XieDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Jinglan PanDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Chunhai XiaoJinshan Branch of Shanghai Sixth People's Hospital, Shanghai, China.
Jian ZhaoDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Xiuhong LuDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Wei XieDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) presents persistent challenges in immunotherapy, as the clinical benefit of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors is frequently constrained by intrinsic and acquired resistance. Central contributors include impaired antigen presentation, T cell exclusion, and the accumulation of immunosuppressive populations that collectively establish a "cold" tumor microenvironment (TME). These mechanisms dampen cytotoxic CD8

Indexed as

Health sciences

Identifiers

PMID41675056
PMCPMC12887263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.